Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Urogen Pharma Ltd (NQ: URGN ) 15.14 -1.34 (-8.13%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Urogen Pharma Ltd < Previous 1 2 3 Next > UroGen Pharma Stock Earns 91 RS Rating June 27, 2024 UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier. Via Investor's Business Daily NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session June 18, 2024 Via Benzinga Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday June 14, 2024 Via Benzinga Hasbro To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday June 14, 2024 Via Benzinga UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug June 13, 2024 The company is working on a treatment for non-muscle invasive bladder cancer. Via Investor's Business Daily Earnings Outlook For UroGen Pharma March 13, 2024 Via Benzinga Recap: UroGen Pharma Q3 Earnings November 14, 2023 Via Benzinga Preview: UroGen Pharma's Earnings November 13, 2023 Via Benzinga URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024 May 13, 2024 URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. Via InvestorPlace Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session March 25, 2024 Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. Via Benzinga URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023 March 14, 2024 URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. Via InvestorPlace The Latest Analyst Ratings for UroGen Pharma October 04, 2023 Via Benzinga Where UroGen Pharma Stands With Analysts July 31, 2023 Via Benzinga Recap: UroGen Pharma Q1 Earnings May 11, 2023 Via Benzinga UroGen Pharma Earnings Preview March 15, 2023 Via Benzinga Earnings Scheduled For March 14, 2024 March 14, 2024 Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. Via Benzinga UroGen Pharma's Return On Capital Employed Overview December 20, 2022 Via Benzinga Two Months After Hamas Attacks, Gaza Conflict Intensifies As Ceasefire Efforts Falter December 07, 2023 Two months after Hamas attacks, US President Biden, UNSC & King of Jordan call for ceasefire. Israeli stocks rise, US envoy to UN against ceasefire. Investigations into civilian casualties & use of... Via Benzinga Cathie Wood's ARK Israel Innovative Tech ETF Braces For Impact Amid Regional Warfare: 10 Stocks To Watch October 09, 2023 Discover how Cathie Wood's ARK Israel Innovative Tech ETF responds to the Israel-Hamas conflict. Explore its portfolio performance and top Israeli stocks to watch amidst geopolitical turmoil. Via Benzinga Topics ETFs $10 Trillion Added In Market Cap; 2023’s Best And Worst Through July August 01, 2023 The US stock market has now seen an increase in market cap of roughly $10 trillion from its bear market low last October through the end of July 2023. Via Talk Markets Why Shares of UroGen Pharma Jumped Friday July 28, 2023 The company released positive top-line results for two studies for a bladder cancer treatment. Via The Motley Fool Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet July 28, 2023 Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be... Via Benzinga Why NICE Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session August 17, 2023 Gainers PhenomeX Inc. (NASDAQ: CELL) shares surged 138.3% to $0.9532. Bruker Corporation and PhenomeX reported a $108 million definitive agreement for Bruker to acquire PhenomeX in an all-cash... Via Benzinga Enphase Energy, Sanofi, Ford And Other Big Stocks Moving Lower In Friday's Pre-Market Session July 28, 2023 U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session. Via Benzinga Why UroGen Pharma Stock Is Gaining Today? July 27, 2023 UroGen Pharma Ltd (NASDAQ: URGN) shares are surging after the company released topline data from its Phase 3 trials ATLAS and ENVISION studying UGN-102 (mitomycin) for intravesical solution in patients... Via Benzinga Earnings Scheduled For August 10, 2023 August 10, 2023 Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. Via Benzinga Earnings Scheduled For May 11, 2023 May 11, 2023 Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its... Via Benzinga Earnings Scheduled For March 16, 2023 March 16, 2023 Companies Reporting Before The Bell • KVH Industries (NASDAQ:KVHI) is projected to report quarterly earnings at $0.03 per share on revenue of $34.29 million. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2023 February 08, 2023 Via Benzinga Earnings Scheduled For November 10, 2022 November 10, 2022 Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter. Via Benzinga < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.